Element Biosciences is a technology company.
Element Biosciences has raised $560.0M across 2 funding rounds.
Element Biosciences has raised $560.0M in total across 2 funding rounds.
Element Biosciences has raised $560.0M in total across 2 funding rounds.
Element Biosciences's investors include Foresite Capital, Gradient Ventures, Great Oaks Venture Capital, Presight Capital, Saga, venBio, Venrock, Konstantin von Unger, Louis Beryl, Zachary Hargreaves.
Element Biosciences is a multi-disciplinary life science company developing disruptive DNA sequencing and multiomics technologies for research markets, centered on its benchtop AVITI™ system powered by proprietary avidite base chemistry (ABC™).[1][3][4][7] Launched in 2022, the AVITI enables affordable, high-quality genomic sequencing for academia, biotech, cancer research, agriculture, and pharma, solving the problem of high costs, limited access, and dependency on external facilities by allowing in-house, rapid analysis that accelerates discoveries.[1][2][3] The company serves diverse labs with products like AVITI24™, expanding to 5D multiomics (genomics, transcriptomics, proteomics, morphology, and dynamics), generating over $25 million in 2023 revenue with 160+ commercial orders and the fastest growth among peers.[3][4]
Element Biosciences was co-founded by Molly He, PhD, who serves as CEO, with a vision to revolutionize sequencing accessibility worldwide from its inception.[1][3][4] The idea emerged from recognizing the need for a platform that pushes innovation boundaries, starting with DNA sequencing but designed to evolve into broader molecular analysis of DNA components and interactions.[1] Key early traction came with the 2022 AVITI launch, which redefined benchtop sequencing through superior accuracy, speed, and cost, quickly gaining adoption across industries and setting the stage for multiomics expansions announced in 2024.[1][3][4][5]
Element Biosciences rides the multiomics trend, integrating genomics with proteomics, transcriptomics, and spatial morphology to provide comprehensive biological insights unattainable via single-omics, fueling precision medicine, drug discovery, and functional genomics.[2][3][4] Timing aligns with rising demand for affordable, in-lab sequencing amid escalating costs from competitors, democratizing access for smaller labs and pharma to de-risk early discovery, map gene functions, and co-develop diagnostics/therapies.[1][2][3] Market forces like CRISPR advancements and AI-driven analytics (e.g., partnerships like SOPHiA GENETICS) favor its high-throughput, rapid workflows, positioning Element to influence the ecosystem by accelerating therapeutic pipelines and broadening genomic research globally.[3][8]
Element's roadmap points to ongoing AVITI evolutions, including Teton™ CytoProfiling, certified service providers, and deeper multiomics like cellular morphology phenotyping post-CRISPR, with potential for direct DNA/RNA sequencing in cells.[3][4][5][8] Trends in 5D multiomics, AI integration, and precision medicine will shape its path, enhancing pharma innovation and research speed. Its influence may grow by challenging incumbents on price/performance, fostering a more inclusive biology research era—echoing its founding goal to empower global scientists for life-impacting discoveries.[1][2][3]
Element Biosciences has raised $560.0M across 2 funding rounds. Most recently, it raised $280.0M Series D in July 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2024 | $280.0M Series D | Foresite Capital, Gradient Ventures, Great Oaks Venture Capital, Presight Capital, Saga, venBio, Venrock, Konstantin von Unger, Louis Beryl, Zachary Hargreaves | |
| Jun 1, 2021 | $280.0M Series C | Foresite Capital, Gradient Ventures, Great Oaks Venture Capital, Presight Capital, Saga, venBio, Venrock, Konstantin von Unger, Louis Beryl, Zachary Hargreaves |